Cargando…

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis

BACKGROUND: It is estimated that acute bacterial skin and skin structure infections (ABSSSI) account for nearly 10% of hospital admissions and 3.4-3.8 million emergency department visits per year in the United States. Analyses of hospital discharge records indicate 74% of ABSSSI admissions involve e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Ivar S., Wu, Elizabeth, Fan, Weihong, Lodise, Thomas P., Nicolau, David P., Dufour, Scott, Cyr, Philip L., Sulham, Katherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397907/ https://www.ncbi.nlm.nih.gov/pubmed/27231802 http://dx.doi.org/10.18553/jmcp.2016.22.6.752

Ejemplares similares

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis
por: Jensen, Ivar S., et al.
Publicado: (2015)

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018)

Values-Based Foundation for a U.S. Single Payer Health System Model
por: Markowitz, Walter, et al.
Publicado: (2021)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway
por: Whittaker, Cristen, et al.
Publicado: (2020)

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies
por: Estrada, Sandy, et al.
Publicado: (2020)

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective
por: Liu, Jinan, et al.
Publicado: (2021)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
por: Lodise, Thomas, et al.
Publicado: (2020)

The Impact of Global Budgeting on the Efficiency of Healthcare under a Single-Payer System in Taiwan
por: Yang, Shao-Wei, et al.
Publicado: (2021)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
por: Anastasio, Patrick J., et al.
Publicado: (2017)

Common Era sea-level budgets along the U.S. Atlantic coast
por: Walker, Jennifer S., et al.
Publicado: (2021)

Patient Preferences in the Emergency Department (ED) Before Treatment for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2017)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

EE422 Healthcare Costs Associated with Severe VS Moderate and Mild COVID-19 - a US Payer Perspective
por: Holy, C, et al.
Publicado: (2022)

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure
por: Lodise, Thomas P., et al.
Publicado: (2017)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

Estimated Budget Impact of Adopting the Affordable Care Act’s Required Smoking Cessation Coverage on United States Healthcare Payers
por: Baker, Christine L., et al.
Publicado: (2016)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective
por: Lin, J., et al.
Publicado: (2014)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments
por: Bookstaver, P Brandon, et al.
Publicado: (2018)

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
por: Yang, Jingyan, et al.
Publicado: (2021)

Benchmarking HIV Quality Measures Across US Payer Types
por: Priest, Julie L., et al.
Publicado: (2020)

1439. Epidemiology and 12- Month Antibiotic Use in the Outpatient Setting among Adult Patients with Complicated Urinary Tract Infections: A Retrospective Database Analysis
por: Lodise, Thomas, et al.
Publicado: (2021)

Budget impact analysis of PCSK9 inhibitors costs from a community payers’ perspective in Apulia, Italy
por: Brunetti, Natale Daniele, et al.
Publicado: (2019)

Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership
por: Miller, Lesley-Ann, et al.
Publicado: (2016)

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
por: Helton, Brittany, et al.
Publicado: (2020)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_129qahej7vujuppbt0fbd2sfa8